Stallion India Fluorochemicals reported a strong FY 2025-26 performance with total income up 14.4% to Rs 434.12 crore and PAT rising 35.6% to Rs 43.84 crore. The company is aggressively expanding into specialty gases, backed by a successful Rs 363.93 crore rights issue. Investors should note the strategic shift toward integrated fluorochemicals, with major projects underway in Rajasthan and new international collaborations for helium supply.
Stallion India Fluorochemicals FY26 Profit Surges 35.6%
Revenue rose 14.1% to Rs 430.68 crore, while net worth jumped to Rs 680.60 crore.
Reader Takeaway: Strong profit growth and successful capital raising bolster the balance sheet, though project execution risks remain critical.
What just happened
Stallion India Fluorochemicals announced its FY 2025-26 annual results, showcasing a significant improvement in profitability. The company’s Profit After Tax reached Rs 43.84 crore, up from Rs 32.33 crore in the previous year. Revenue from operations grew to Rs 430.68 crore, supported by an improved EBITDA margin of 14.13%. A notable reduction in finance costs from Rs 6.15 crore to Rs 0.89 crore underscores the company's deleveraging efforts.
Why this matters
The company is transforming into an integrated fluorochemicals and specialty gases platform. The successful completion of a rights issue, which raised over Rs 360 crore, provides the capital runway for significant capex projects. This includes a new 10,000 MT R-32 facility in Rajasthan and a planned Rs 200 crore investment in HFO manufacturing, positioning the company to capture higher demand in the specialty gases segment.
Strategic Initiatives
- The company has secured environmental clearance for its Bhilwara R-32 plant.
- It has formalized a partnership with Sharjah Oxygen Company to secure stable liquid helium supplies.
- A strategic collaboration with Portugal-based SYS ADVANCE will enhance its capabilities in Helium recovery and liquefaction.
Governance and Legal Update
The board appointed Ms. Swati Kumari Ghosh as an Independent Director in May 2026. The company also reached a settlement with Zhejiang Sanmei Chemical Industry Co. Ltd, resolving a dispute with a payout of USD 1.25 million. Management noted that corrective steps have been implemented following minor compliance observations by the secretarial auditor.
What to track next
Investors should monitor the construction timelines for the Bhilwara facility and the commencement of the HFO plant, as these are the primary drivers for future margin expansion and revenue growth.